Nanomedicine prompts RNA to make protein-based drugs to treat diseases. Now we can fine-tune protein production by dialling ...

Nucleic acid-based therapeutics, including antisense oligonucleotides (ASO), small interfering RNA (siRNA), messenger RNA (mRNA), immunomodulatory DNA/RNA, and gene-editing guide RNA (gRNA), hold ...

Advances in mRNA design continue to shape the next generation of therapeutic development. Yet, achieving strong and sustained protein expression remains a persistent challenge across platforms.

Once the most successful mRNA-based LNP was tested in 3D in vitro models, the fluorescent dye continued to facilitate ...

Imagine a cancer treatment that precisely targets malignant cells, leaving healthy ones untouched. Consider, also, a cancer treatment that corrects abnormal protein synthesis to produce healthy ...

Making proteins for research or therapies often starts with cell-line development. In many applications, genetic engineering is used to optimize a cell line for producing high levels of the intended ...

The mRNA therapeutics industry faces a critical manufacturing challenge that threatens both product safety and commercial viability. Double-stranded RNA (dsRNA) formation during in vitro transcription ...

Most people don’t enjoy getting shots for treatments or vaccines. So, researchers are working to create more medicines, such as those made from messenger RNA (mRNA), that can be sprayed and inhaled. A ...

Recent trends in cancer distribution and survival outcomes among adolescent and young adult patients: A national data analysis.